Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2295-2302

  Kikuchi, Akifumi ^a   Ishikawa, Toshiaki ^a   Mogushi, Kaoru ^a   Ishiguro, Megumi ^a   Iida, Satoru ^a   Mizushima, Hiroshi ^a   Uetake, Hiroyuki ^a   Tanaka, Hiroshi ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

biomarker; colorectal cancer; DNA copy number analysis; gene expression analysis; microarray

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CASEIN KINASE; CYCLIN DEPENDENT KINASE 1; MESSENGER RNA; NUCLEAR PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL CYCLE PROGRESSION; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FALSE POSITIVE RESULT; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCKS1 GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SENSITIVITY ANALYSIS; SYNPR GENE; TMEM63A GENE; TUMOR GENE; UPREGULATION;

ANALYSIS OF VARIANCE; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84874851251     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27911     Document Type: Article

References (39)

1. Ricchi P, Zarrilli R, Di Palma A, et al. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003; 88: 803-7.
2. Tsukuma H, Ajiki W, Oshima A,. Cancer incidence in Japan. Gan To Kagaku Ryoho 2004; 31: 840-6.
3. Matsuda T, Marugame T, Kamo KI, et al. Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 2010; 40: 1192-200.
4. Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007; 141: 67-75.
5. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005; 365: 153-65.
6. Ross JS, Torres-Mora J, Wagle N, et al. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol 2010; 134: 478-90.
7. Shih W, Chetty R, Tsao MS,. Expression profiling by microarrays in colorectal cancer (Review). Oncol Rep 2005; 13: 517-24.
8. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22: 1564-71.
9. Nannini M, Pantaleo MA, Maleddu A, et al. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 2009; 35: 201-9.
10. Nakao M, Kawauchi S, Furuya T, et al. Identification of DNA copy number aberrations associated with metastases of colorectal cancer using array CGH profiles. Cancer Genet Cytogenet 2009; 188: 70-6.
11. Kurashina K, Yamashita Y, Ueno T, et al. Chromosome copy number analysis in screening for prognosis-related genomic regions in colorectal carcinoma. Cancer Sci 2008; 99: 1835-40.
12. Yamamoto S, Midorikawa Y, Morikawa T, et al. Identification of chromosomal aberrations of metastatic potential in colorectal carcinoma. Genes Chromosomes Cancer 2010; 49: 487-96.
13. Aragane H, Sakakura C, Nakanishi M, et al. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 2001; 94: 623-9.
14. Yau C, Holmes CC,. CNV discovery using SNP genotyping arrays. Cytogenet Genome Res 2008; 123: 307-12.
15. Tsafrir D, Bacolod M, Selvanayagam Z, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006; 66: 2129-37.
16. Pollack JR, Sørlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002; 99: 12963-8.
17. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002; 62: 6240-5.
18. Phillips JL, Hayward SW, Wang Y, et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001; 61: 8143-9.
19. Ramakrishna M, Williams LH, Boyle SE, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 2010; 5: e9983.
20. Cardoso J, Boer J, Morreau H, et al. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 2007; 1775: 103-37.
21. Yoshida T, Kobayashi T, Itoda M, et al. Clinical omics analysis of colorectal cancer incorporating copy number aberrations and gene expression data. Cancer Inform 2010; 9: 147-61.
22. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65: 1678-86.
23. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002; 13: 1977-2000.
24. Drosos Y, Kouloukoussa M, Østvold AC, et al. NUCKS overexpression in breast cancer. Cancer Cell Int 2009; 9: 19.
25. Sargent LM, Ensell MX, Ostvold AC, et al. Chromosomal changes in high- and low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains. Toxicol Appl Pharmacol 2008; 233: 81-91.
26. Thompson HG, Harris JW, Wold BJ, et al. Identification and confirmation of a module of coexpressed genes. Genome Res 2002; 12: 1517-22.
27. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14: 4376-86.
28. Naylor TL, Greshock J, Wang Y, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005; 7: R1186-R1198.
29. Diep CB, Kleivi K, Ribeiro FR, et al. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 2006; 45: 31-41.
30. Platzer P, Upender MB, Wilson K, et al. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002; 62: 1134-8.
31. Walaas SI, Ostvold AC, Laland SG,. Phosphorylation of P1, a high mobility group-like protein, catalyzed by casein kinase II, protein kinase C, cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II. FEBS Lett 1989; 258: 106-8.
32. Maelandsmo GM, Ostvold AC, Laland SG,. Phosphorylation of the high-mobility-group-like protein P1 by casein kinase-2. Eur J Biochem 1989; 184: 529-34.
33. Ostvold AC, Norum JH, Mathiesen S, et al. Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem 2001; 268: 2430-40.
34. Meijer L, Ostvold AC, Walass SI, et al. High-mobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. Eur J Biochem 1991; 196: 557-67.
35. Obrand DI, Gordon PH,. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40: 15-24.
36. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
37. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-9.
38. Wolpin BM, Mayer RJ,. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-310.
39. Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007; 109: 1082-9.